<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966355</url>
  </required_header>
  <id_info>
    <org_study_id>TPSTOT</org_study_id>
    <nct_id>NCT00966355</nct_id>
  </id_info>
  <brief_title>Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding</brief_title>
  <official_title>RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide
      in patients with variceal bleeding for the control of variceal bleeding in combination with
      endoscopic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients who are suspected to have variceal bleedings, pharmacologic therapy with
      vasoactive drugs such as terlipressin, somatostatin, and octreotide is recommended as soon as
      possible, even before endoscopy. However, it is still unclear whether the efficacies of these
      drugs are same or not. This study is performed to compare the efficacy of terlipressin,
      somatostatin, and octreotide in patients with variceal bleeding for the control of variceal
      bleeding in combination with endoscopic therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death)</measure>
    <time_frame>5 days after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Active Bleeding During the First Endoscopic Exam, Needing Blood Transfusion for 5 Days, Experiencing Adverse Effects</measure>
    <time_frame>5 days after enrollment</time_frame>
    <description>at least one of the three criteria</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1034</enrollment>
  <condition>Variceal Bleeding, Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Terlipressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treat with terlipressin IV for 5 days and endoscopic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Somatostatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treat with somatostatin IV for 5 days and endoscopic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treat with octreotide IV for 5 days and endoscopic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days</description>
    <arm_group_label>Terlipressin</arm_group_label>
    <other_name>Glypressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days</description>
    <arm_group_label>Somatostatin</arm_group_label>
    <other_name>Somatosan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days</description>
    <arm_group_label>Octreotide</arm_group_label>
    <other_name>Sandostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver cirrhosis

          -  age between 16 and 75 years

          -  Patients who have upper GI bleeding symptoms (hematemesis or melena) within 24 hours
             before enrollment

          -  Patients whose systolic blood pressure &lt;100 mmHg or pulse rate &gt;100/min at the
             enrollment

          -  Patients who were not performed endoscopic or pharmacologic therapy for varices

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Positive anti-HIV Ab

          -  A history of severe side-effects or contraindications to study drugs

          -  Severe cardiovascular diseases: acute myocardial infarction, A-V block, congestive
             heart failure, ischemic heart disease, hypertension (systolic blood pressure &gt;170 mmHg
             or diastolic pressure &gt;100 mmHg)

          -  Chronic renal failure

          -  Hepatocellular carcinoma with protal vein thrombosis

          -  Coexisting malignancy except hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Ho Um, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <results_first_submitted>April 23, 2013</results_first_submitted>
  <results_first_submitted_qc>August 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2018</results_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Soon Ho Um</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis, Esophagus Disorders, Varicose Veins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with liver cirrhosis presenting with either hematemesis or melena between October 1, 2006 and May 31, 2010 at eleven medical centers distributed throughout Korea.</recruitment_details>
      <pre_assignment_details>failure to fulfill inclusion criteria, no cirrhosis, prior endoscopic therapy within 2 weeks, enrolled within 6 weeks before index bleed, severe cardiovascular diseases, chronic renal failure, hepatocellular carcinoma invading portal vein, other malignancy, pregnancy, HIV-positive, hypersensitivity to the study drugs, or refusal to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Octreotide</title>
          <description>treat with octreotide IV for 5 days and endoscopic treatment
Octreotide : loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Somatostatin</title>
          <description>treat with somatostatin IV for 5 days and endoscopic treatment
Somatostatin : loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days</description>
        </group>
        <group group_id="P3">
          <title>Terlipressin</title>
          <description>treat with terlipressin IV for 5 days and endoscopic treatment
Terlipressin : loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="344"/>
                <participants group_id="P2" count="345"/>
                <participants group_id="P3" count="345"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="259"/>
                <participants group_id="P3" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>non-variceal bleeding on endoscopy</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>newly diagnosed advanced HCC</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Octreotide</title>
          <description>treat with octreotide IV for 5 days and endoscopic treatment
Octreotide : loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Somatostatin</title>
          <description>treat with somatostatin IV for 5 days and endoscopic treatment
Somatostatin : loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Terlipressin</title>
          <description>treat with terlipressin IV for 5 days and endoscopic treatment
Terlipressin : loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="260"/>
            <count group_id="B2" value="259"/>
            <count group_id="B3" value="261"/>
            <count group_id="B4" value="780"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="223"/>
                    <measurement group_id="B4" value="661"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="10.0"/>
                    <measurement group_id="B2" value="53.1" spread="9.7"/>
                    <measurement group_id="B3" value="52.9" spread="9.2"/>
                    <measurement group_id="B4" value="53.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="223"/>
                    <measurement group_id="B4" value="666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death)</title>
        <time_frame>5 days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octreotide</title>
            <description>treat with octreotide IV for 5 days and endoscopic treatment
Octreotide : loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Somatostatin</title>
            <description>treat with somatostatin IV for 5 days and endoscopic treatment
Somatostatin : loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Terlipressin</title>
            <description>treat with terlipressin IV for 5 days and endoscopic treatment
Terlipressin : loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="216"/>
                    <measurement group_id="O3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Bleeding During the First Endoscopic Exam, Needing Blood Transfusion for 5 Days, Experiencing Adverse Effects</title>
        <description>at least one of the three criteria</description>
        <time_frame>5 days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Octreotide</title>
            <description>treat with octreotide IV for 5 days and endoscopic treatment
Octreotide : loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Somatostatin</title>
            <description>treat with somatostatin IV for 5 days and endoscopic treatment
Somatostatin : loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Terlipressin</title>
            <description>treat with terlipressin IV for 5 days and endoscopic treatment
Terlipressin : loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Active Bleeding During the First Endoscopic Exam, Needing Blood Transfusion for 5 Days, Experiencing Adverse Effects</title>
          <description>at least one of the three criteria</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Octreotide</title>
          <description>treat with octreotide IV for 5 days and endoscopic treatment
Octreotide : loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Somatostatin</title>
          <description>treat with somatostatin IV for 5 days and endoscopic treatment
Somatostatin : loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Terlipressin</title>
          <description>treat with terlipressin IV for 5 days and endoscopic treatment
Terlipressin : loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>Diarrhea developed in 2 patients. Both patients were included in the octreotide group.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="261"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Soon Ho Um</name_or_title>
      <organization>Korea University College of Medicine</organization>
      <phone>+82-2-920-5019</phone>
      <email>umsh@korea.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

